Etretinate

This MedLibrary.org supplementary page on Etretinate is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:

Etretinate
Systematic (IUPAC) name
ethyl 9-(4-methoxy-2,3,6-trimethyl-phenyl)- 3,7-dimethyl-nona- 2,4,6,8-tetraenoate
Identifiers
CAS number 54350-48-0
ATC code D05BB01
PubChem 3312
DrugBank APRD00966
Chemical data
Formula C23H30O3 
Mol. mass 354.483 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life 120 days
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes Oral

Etretinate (trade name Tigason) is a medication used to treat severe psoriasis. It was removed from the United States market in 1998 and the Canadian market in 1996, due to the high risk of birth defects.

Etretinate has been replaced by acitretin, a metabolite of etretinate.

Precautions

  • Etretinate is a teratogen, and may cause birth defects long after use. Therefore, etretinate should only be used if one is never to get pregnant.
  • Etretinate should be avoided in children, as it may interfere with growth of bone.

Side effects

Wikipedia content modification information:

  • This page was last modified on 3 June 2008, at 06:34.

Wikipedia Authorship and Review

Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.

Wikipedia Usage Guidelines

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Etretinate".

The URL for this specific entry is:

All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.